07X Stock Chart & Stats
€1.53
€0.02(1.59%)
At close: 4:00 PM EDT
€1.53
€0.02(1.59%)
Day’s Range― - ―
52-Week Range€0.93 - €4.61
Previous CloseN/A
Volume0.00
Average Volume (3M)275.00
Market Cap
€38.66M
Enterprise Value€51.06
Total Cash (Recent Filing)€18.73M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Nov 11, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.79
Shares Outstanding42,679,058
10 Day Avg. Volume275
30 Day Avg. Volume275
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-2.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.29Price Target Upside507.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 Enrollment MilestoneFull enrollment in a large, controlled Phase 3 study materially advances buntanetap toward regulatory decision points. The planned six- and 18-month readouts create multiple clinical milestones and could improve the company’s strategic position if efficacy is demonstrated.
No Reported DebtReported absence of debt across periods limits refinancing and interest-rate exposure, preserving more flexibility for a clinical-stage company. This is a meaningful balance-sheet advantage because obligations are not being compounded by borrowing costs while development spending continues.
Governance And Talent-retention FlexibilityApproval of the expanded equity incentive plan gives Annovis greater flexibility to retain employees and align management rewards with development objectives. Stronger governance processes and compensation tools can support execution as the company advances its clinical pipeline.
Bears Say
No Commercial RevenueThe absence of revenue across 2021–2025 and TTM shows the company has not yet established commercial traction or a recurring sales base. Until a product is approved and launched, operating progress depends on development outcomes rather than internally generated business revenue.
Persistent And Worsening Cash BurnConsistently negative operating and free cash flow means research and clinical operations consume cash rather than fund themselves. The sharp TTM deterioration heightens the need for future capital, making financing conditions and potential equity issuance important to sustaining development.
Weakening Balance-sheet ResilienceNegative equity in 2023 and the TTM period, together with assets declining materially from 2021, signals reduced balance-sheet resilience. Even without debt, cumulative losses can narrow financial flexibility and increase reliance on external funding to complete the pipeline.
Annovis Bio News
07X FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was €0.93 and its highest was €4.61 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is €38.66M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is Nov 11, 2026 which is in 53 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Aug 14, 2026. The company reported -€0.345 earnings per share for the quarter, beating the consensus estimate of -€0.391 by €0.046.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -0.26.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 42,679,058 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -€0.345 in its last earnings report, beating expectations of -€0.391. Following the earnings report the stock price went up 0.654%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in DE:07X
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.29 (507.20% Upside)
€9.29 (507.20% Upside)
Blogger Sentiment
Bullish
DE:07X Sentiment 100%
Sector Average 62%
Sector Average 62%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.58%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Annovis Bio
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
07X Stock 12 Month Forecast
Average Price Target
€9.29
▲(507.20% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―